Julius Hoffmann

TL;DR: Results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy and should be guided by immunization strategies.

TL;DR: Results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy and should be guided by immunization strategies.

TL;DR: Describing the ex vivo frequency and phenotype of circulating CD4+ T helper (TH) cells reactive to NR1 protein using antigen-reactive T cell enrichment (ARTE) in patients with NMDAR encephalitis reveals disease-specific functional alterations and challenges the idea that increased pro-inflammatory N MDAR-re active T cells contribute to disease pathogenesis.

TL;DR: The data reveal disease-specific functional alterations of circulating NMDAR-reactive TH cells in patients with N MDAR encephalitis and challenge the idea that increased pro-inflammatory NMDar-re active T cells contribute to disease pathogenesis.

TL;DR: Among 598 human monoclonal antibodies (mAbs) from ten SARS-CoV-2 patients, this article identified 40 strongly neutralizing mAbs, including CV07-209, which achieved IC 50 of 3.1 ng/ml.